Anuh Pharma Ltd Q2 FY27 results (latest), Jul–Sep 2026 →Revenue ₹185 Cr −0.5% YoYSee revenue, profit and what management said. You are viewing Q4 FY23.
AP

Anuh Pharma Ltd

Q4 FY23Pharmaceuticals & Biotechnology

Anuh Pharma Q4 FY23 earnings call: Revenue & Margins

Q4 FY23 investor presentation: what the company reported on revenue, margins and capex.

Anuh Pharma Ltd Q4 FY23 key numbers

Revenue
Operating revenue for the quarter ended 31/03/2023 was Rs. 157.31 Cr, up from Rs. 138.73 Cr in the same quarter of the previous year, showing a year-on-year increase of approximately 13.5%.

As stated in Anuh Pharma Ltd's Q4 FY23 investor presentation · published 24 Sept 2026. Reported figures, not investment advice.

Based on Anuh Pharma Ltd's Q4 FY23 investor presentation. The company has not published an earnings-call transcript for this quarter, so figures here are what the investor presentation reports, not management guidance.

Price₹91
Market cap₹937 Cr
P/E21.2

The short version

Operating revenue for the quarter ended 31/03/2023 was Rs. 157.31 Cr, up from Rs. 138.73 Cr in the same quarter of the previous year, showing a year-on-year increase of approximately 13.5%. Quarterly EBITDA: Rs. 15.27 Cr (up 5% QoQ compared to Rs. 14.54 Cr).

From Anuh Pharma Ltd's Q4 FY23 earnings-call transcript · updated 24 Sept 2026.

Revenue & Sales Performance

  • Operating revenue for the quarter ended 31/03/2023 was Rs. 157.31 Cr, up from Rs. 138.73 Cr in the same quarter of the previous year, showing a year-on-year increase of approximately 13.5%.
  • For the full FY 2023, operating revenue was Rs. 527.49 Cr compared to Rs. 486.65 Cr in FY 2022, an 8% year-on-year growth.
  • Export sales increased by about 26.92% from Rs. 228 Cr in FY 2022 to Rs. 289 Cr in FY 2023.

2 more points from Anuh Pharma Ltd's call on revenue

Create a free account to keep reading this call

Profitability & Margins

See what Anuh Pharma Ltd said on profitability & margins — free account, 30 seconds.

Capital Expenditure Plans

  • Planned Capex of Rs 5 Cr for capacity enhancement to support a target growth rate of 20% (Page 7).
  • Manufacturing capacity at L&L site for corticosteroids enhanced to 12 MTPA (Page 30).
  • Focus on capacity improvements and efficiency.
  • R&D facility: Dedicated 10,000 sq. ft. in-house lab with 16 scientists operational for new product/process development (Page 28).

Top-ranked in Pharmaceuticals & Biotechnology

Ranked on what management guided this quarter

Guidance-ranked
Rev 1Mar 1
2KRM Ayurveda
Rev 1Mar 1
3
Rev 1Mar 2
4
Rev 1Mar 3
5
Rev 1Mar 3
Sign up free to see 3 moreTakes 30 seconds · no cardSign up

Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.

Fundraising & Capital Structure

See what Anuh Pharma Ltd said on fundraising & capital structure — free account, 30 seconds.

Order Book & Pipeline

The key financial and operational data disclosed include: - FY23 total revenue of Rs 537 Cr, with 8.33% top-line growth over FY22. - EBITDA of Rs 57 Cr in FY23, up 9.6% from FY22.

2 more points from Anuh Pharma Ltd's call on order book

Create a free account to keep reading this call

Anuh Pharma Ltd — Quarterly revenue & net profit

Revenue Net profit
Jun 2025Q1 FY26
Sep 2025Q2 FY26
Dec 2025Q3 FY26
Mar 2026Q4 FY26
Jun 2026Q1 FY27
Sep 2026Q2 FY27

Reported quarterly figures (₹ Cr). Latest (Q2 FY27): revenue ₹185 Cr, net profit ₹11 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.

Full financials →

🔎 Who's planning the most growth?

Companies ranked by management's own guidance — revenue, margins, capex and order book, from every earnings call in India.

See rankings →

Arthneeti Pro · Annual

Anuh Pharma Ltd and 15K+ more earnings calls,
for less than your morning chai

Every earnings call, ranking and concall Q&A across all four results seasons.

Secure Razorpay payment · instant access

Frequently Asked Questions

What were Anuh Pharma Ltd Q4 FY23 results?

Operating revenue for the quarter ended 31/03/2023 was Rs. 157.31 Cr, up from Rs. 138.73 Cr in the same quarter of the previous year, showing a year-on-year increase of approximately 13.5%. Quarterly EBITDA: Rs. 15.27 Cr (up 5% QoQ compared to Rs. 14.54 Cr).

What is Anuh Pharma Ltd share price analysis?

Anuh Pharma Ltd currently shows a neutral. The stock trades at a P/E of 21.2 with a market cap of ₹937 Cr. Investors should review the full earnings analysis for detailed insights.

Is Anuh Pharma Ltd planning capital expenditure?

Planned Capex of Rs 5 Cr for capacity enhancement to support a target growth rate of 20% (Page 7).

Keep Anuh Pharma Ltd on your radar — track it to get its next earnings analysis in your feed.

This analysis is AI-generated based on publicly available earnings data and the company's investor presentation. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.